DNTH Dianthus Therapeutics, Inc.
Healthcare$86.60+0.00%OpenMarket Cap: $3.62B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.46
P/S
2702.50
EV/EBITDA
-15.93
DCF Value
$-2.77
FCF Yield
-3.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.3%
Operating Margin
-14318.0%
Net Margin
-847.5%
ROE
-1.8%
ROA
-0.9%
ROIC
-15.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $463.0K | 83.6% | $-46.5M | $-40.8M | $— | — |
| Q4 null | $284.0K | 100.0% | $-69.5M | $97.9M | $— | — |
| FY null | $2.0M | 100.0% | $-177.9M | $-162.3M | $— | — |
| Q3 null | $396.0K | 100.0% | $-40.3M | $-36.8M | $— | — |
| Q2 null | $193.0K | 100.0% | $-34.9M | $-31.6M | $— | — |
| Q1 null | $1.2M | 100.0% | $-33.2M | $-29.5M | $— | — |
| Q4 null | $1.3M | 100.0% | $-31.9M | $-28.4M | $— | — |
| FY null | $6.2M | 100.0% | $-101.9M | $-85.0M | $— | — |
| Q3 null | $2.2M | 100.0% | $-29.9M | $-25.2M | $— | — |
| Q2 null | $1.9M | 100.0% | $-22.2M | $-17.6M | $— | — |
| Q1 null | $874.0K | 100.0% | $-17.8M | $-13.7M | $— | — |
| Q4 2023 | $457.0K | 100.0% | $-13.0M | $-10.6M | $-2.33 | — |